http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 24 Aug 2026 07:04:39 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/EU+grants+Vanda%27s+imsidolimab+first+orphan+status+for+rare+skin+disease/26964124.html <p>Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the European Commission has granted Orphan Designation to its investigational drug imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), a rare inflammatory skin disease.</p><p>According to the company's press release, this marks the first time the European Commission has granted orphan designation for a drug targeting GPP in the European Union. The designation followed a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products.</p><p>GPP is characterized by widespread pustular eruptions, systemic inflammation, and complications that can lead to increased mortality. Imsidolimab inhibits IL-36 receptor signaling, which is implicated in the http://www.streetinsider.com/Corporate+News/EU+grants+Vanda%27s+imsidolimab+first+orphan+status+for+rare+skin+disease/26964124.html Mon, 24 Aug 2026 07:04:39 -0400 VNDA http://www.streetinsider.com/FDA/EU+grants+Vanda%27s+imsidolimab+first+orphan+status+for+rare+skin+disease/26964124.html <p>Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced that the European Commission has granted Orphan Designation to its investigational drug imsidolimab for the treatment of Generalized Pustular Psoriasis (GPP), a rare inflammatory skin disease.</p><p>According to the company's press release, this marks the first time the European Commission has granted orphan designation for a drug targeting GPP in the European Union. The designation followed a positive opinion from the European Medicines Agency's Committee for Orphan Medicinal Products.</p><p>GPP is characterized by widespread pustular eruptions, systemic inflammation, and complications that can lead to increased mortality. Imsidolimab inhibits IL-36 receptor signaling, which is implicated in the http://www.streetinsider.com/FDA/EU+grants+Vanda%27s+imsidolimab+first+orphan+status+for+rare+skin+disease/26964124.html Mon, 24 Aug 2026 07:04:39 -0400 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/Press+Releases/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.dc.wash" idsrc="xmltag.org" >WASHINGTON</location></span>, <span class="legendSpanClass"><chron>Aug. 24, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:VNDA" idsrc="xmltag.org" >Vanda Pharmaceuticals Inc.</span> (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the <span value="ACORN:6001200484" idsrc="xmltag.org" >European Commission</span>, based on the positive opinion received from the <span value="ACORN:3106670068" idsrc="xmltag.org" >European Medicines Agency's</span> (EMA) <span>Committee for Orphan Medicinal Products</span> (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US <span value="ACORN:0682203466" idsrc="xmltag.org">Food and Drug Administration</span> (<span value="ACORN:0682203466" idsrc="xmltag.org">FDA</span>) and <location http://www.streetinsider.com/PRNewswire/Vanda+Pharmaceuticals+Granted+Orphan+Designation+for+Imsidolimab+for+the+Treatment+of+Generalized+Pustular+Psoriasis+by+the+European+Commission/26964043.html Mon, 24 Aug 2026 07:00:00 -0400 A.05963196 A.06822034 A.31066700 A.50202117 A.60012004 O.00840259 O.01304637 O.05375760 O.20026344 O.22422661 O.37382289 VNDA